Skip to main content

BioMedNewsBreaks – RYVYL Inc. (NASDAQ: RVYL) Reduces Debt by $60M+ Through Second Exchange Agreement

RYVYL (NASDAQ: RVYL), a leading innovator of payment-transaction solutions leveraging proprietary blockchain ledger and electronic token technology for the diverse international markets, has entered into a second exchange agreement with an existing noteholder. According to the announcement, the agreement will forbear the note repayment requirement until April 5, 2025, and exchange the outstanding principal in a new authorized series of preferred stock. The agreement outlines a series of exchanges as well as a cash payment of $3 million, which the company has agreed to make for an additional $3,600,000 reduction in principal of the note. At the anticipated closing date of the agreement, which is on or around Nov. 29, 2023, RYVYL’s debt is expected to be reduced to $19,700,000. “We believe that the noteholder’s agreement to convert a significant portion of its debt holdings to equity in the company evidences its continued support and its belief in RYVYL’s core mission,” said RYVYL chair Ben Errez in the press release. “Once completed, we will have a stronger balance sheet, significantly increasing net shareholder equity and reducing outstanding debt by more than $60 million. It is our hope that by bringing net shareholder equity back into compliance with NASDAQ’s listing standards, we will be able to maintain the listing of our common stock on NASDAQ as we look to continue to grow our disruptive payment transaction technology to diverse global markets.”

To view the full press release, visit

About RYVYL Inc.

RYVYL’s cutting-edge blockchain, ledger-based platform offers a seamless and secure payment experience tailored for the diverse and ever-evolving global market. By harnessing the power of blockchain technology, the company ensures unparalleled security, transparency and immutability in all transactions. RYVYL’s commitment to simplicity guarantees a user-friendly interface accessible to everyone, while robust compliance measures instill trust and confidence across borders and regulatory landscapes. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.